Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.73 |
| ▸ | RET | P07949 | 5/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | KDR | P35968 | 12/20 | 0.69 |
| ▸ | FLT4 | P35916 | 7/20 | 0.69 |
| ▸ | KIT | P10721 | 3/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.67 |
| ▸ | AURKA | O14965 | 4/20 | 0.67 |
| ▸ | FLT1 | P17948 | 4/20 | 0.67 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.67 |
| ▸ | STK3 | Q13188 | 3/20 | 0.67 |
| ▸ | CSF1R | P07333 | 3/20 | 0.67 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.67 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.67 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.67 |
| ▸ | MET | P08581 | 2/20 | 0.67 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111143 | 1.00 | FLT3 (0.73) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL14097467 | 0.89 | FGFR1 (0.72) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL24166902 | 0.88 | FGFR1 (0.71) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL8674189 | 0.86 | FGFR1 (0.69) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL8674185 | 0.86 | FGFR1 (0.69) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL6321986 | 0.86 | ALK (0.58) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL6321989 | 0.86 | ALK (0.58) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL3793962 | 0.86 | ALK (0.73) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL3793960 | 0.86 | ALK (0.73) | FLT3FGFR1PDGFRBALKRET | |
| SCHEMBL3798589 | 0.86 | KDR (0.70) | FLT3FGFR1PDGFRBALKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | claimed |
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1446117-A4 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1255752-B1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | SUGEN, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035009-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003031438-A1 | 3-[4-(SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE]-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K3, CDK2 | FLT3 403/4885FGFR1 848/4885PDGFRB 687/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | FLT3 422/4885FGFR1 1037/4885PDGFRB 1015/4885 |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | PDPK1, MKNK1, PKN2 | FLT3 1652/4885FGFR1 1284/4885PDGFRB 948/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | FLT3 4311/4885FGFR1 4752/4885PDGFRB 4421/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | FLT3 692/4885FGFR1 1091/4885PDGFRB 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.